JAZZ Stock Forecast: Jazz Pharmaceuticals Plc Price Predictions for 2026-2027
The 22 Wall Street analysts covering Jazz Pharmaceuticals Plc hold a median 12-month price target of $300 — +29.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Jazz Pharmaceuticals Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
JAZZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on JAZZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.9% from it.
Of the 20 most recent actions, 16 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Morgan Stanley | Maintains | Overweight | $319 → $324 |
| 12 Nov 2026 | Piper Sandler | Maintains | Overweight | $310 → $330 |
| 3 Nov 2026 | Barclays | Maintains | Overweight | $271 → $275 |
| 3 Nov 2026 | JP Morgan | Maintains | Overweight | $300 → $310 |
| 3 Nov 2026 | Morgan Stanley | Maintains | Overweight | $314 → $319 |
| 3 Nov 2026 | RBC Capital | Maintains | Outperform | $296 → $305 |
| 28 Oct 2026 | JP Morgan | Maintains | Overweight | $276 → $300 |
| 21 Oct 2026 | Morgan Stanley | Maintains | Overweight | $322 → $314 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $299 → $296 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $281 → $286 |
| 30 Sept 2026 | Citigroup | Initiates | Buy | $325 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $337 |
| 11 Sept 2026 | UBS | Maintains | Buy | $315 → $337 |
| 10 Sept 2026 | Barclays | Maintains | Overweight | $270 → $271 |
| 26 Aug 2026 | Deutsche Bank | Maintains | Buy | $287 → $300 |
| 26 Aug 2026 | Morgan Stanley | Maintains | Overweight | $283 → $322 |
| 26 Aug 2026 | Needham | Maintains | Buy | $292 → $310 |
| 26 Aug 2026 | Truist Securities | Maintains | Buy | $264 → $281 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | $280 → $283 |
| 4 Aug 2026 | Baird | Maintains | Outperform | $252 → $280 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for JAZZ.
This page is one stock. Monday covers all of them.
JAZZ appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
JAZZ vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Jazz Pharmaceuticals Plc returned +31.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
JAZZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 68.1×
- Price / sales
- 3.1×
- Price / book
- 3.5×
- EV / EBITDA
- 8.7×
Cheaper than 12% of US stocks
Cheaper than 35% of US stocks
Cheaper than 26% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 90.4%
- Operating margin
- 27.4%
- Net margin
- —
Higher than 96% of US stocks
Higher than 86% of US stocks
- Return on equity
- 5.1%
- Return on assets
- 6.9%
- Dividend yield
- —
Higher than 52% of US stocks
Higher than 84% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jazz Pharmaceuticals Plc has a market value of $14.8B and an enterprise value of $17.6B.
Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 15.5% year on year.
Net income over the same four quarters: $940.8M, a 20.4% net margin.
Diluted earnings per share, trailing twelve months: $14.50.
Free cash flow in the twelve months to 30 June 2026: $1.3B.
Trailing P/E: 68.1×; forward P/E: 8.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Jazz Pharmaceuticals Plc employs 2,890 people — $1.6M of revenue per employee.
Data provided by Twelve Data
JAZZ and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at JAZZ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Jazz Pharmaceuticals Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about JAZZ
What is the JAZZ stock price forecast for 2026-2027?
The 22 Wall Street analysts covering Jazz Pharmaceuticals Plc have a median 12-month price target of $300, with estimates ranging from $220 to $330. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is JAZZ stock a buy right now?
Of the 22 analysts covering Jazz Pharmaceuticals Plc, 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jazz Pharmaceuticals Plc 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank JAZZ?
As at 21 Nov 2026, Jazz Pharmaceuticals Plc ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
Will JAZZ stock go up?
No one can know that. What the data says: the median 12-month target from 22 analysts implies +29.9% from the last close, and Ticker Nerd's factor model ranks Jazz Pharmaceuticals Plc 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the JAZZ stock forecast for 2030?
No analyst covering Jazz Pharmaceuticals Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAZZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $220 to $330 over the next 12 months.
How has JAZZ stock performed over the past year?
Jazz Pharmaceuticals Plc returned +31.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Jazz Pharmaceuticals Plc do?
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options.
About Jazz Pharmaceuticals Plc.
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.
CEO Ms. Renee D. Gala · 2,890 employees · Ireland · https://www.jazzpharma.com